tiprankstipranks
Advertisement
Advertisement

TRVI Stock Latest News

Trevi Therapeutics Advances IPF Program with Completed NAL ER Safety Study
Company AnnouncementsTrevi Therapeutics Advances IPF Program with Completed NAL ER Safety Study
2d ago
TRVI
Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board
PremiumThe Fly
Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board
14d ago
SER
TRVI
Trevi Therapeutics initiated with an Outperform at BMO Capital
PremiumThe Fly
Trevi Therapeutics initiated with an Outperform at BMO Capital
16d ago
TRVI
Trevi Therapeutics initiated with an Outperform at BMO Capital
PremiumThe Fly
Trevi Therapeutics initiated with an Outperform at BMO Capital
16d ago
TRVI
Trevi Therapeutics price target raised to $31 from $21 at B. Riley
PremiumThe Fly
Trevi Therapeutics price target raised to $31 from $21 at B. Riley
16d ago
TRVI
Trevi Therapeutics price target raised to $24 from $21 at H.C. Wainwright
PremiumThe FlyTrevi Therapeutics price target raised to $24 from $21 at H.C. Wainwright
17d ago
TRVI
Trevi Therapeutics price target raised to $40 from $29 at Clear Street
Premium
The Fly
Trevi Therapeutics price target raised to $40 from $29 at Clear Street
17d ago
GSK
TRVI
Trevi Therapeutics rises 10.9%
Premium
The Fly
Trevi Therapeutics rises 10.9%
19d ago
TRVI
Trevi Therapeutics rises 10.4%
PremiumThe Fly
Trevi Therapeutics rises 10.4%
19d ago
TRVI
Trevi Therapeutics management to meet with Cantor Fitzgerald
PremiumThe Fly
Trevi Therapeutics management to meet with Cantor Fitzgerald
23d ago
TRVI
Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial
PremiumCompany Announcements
Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial
26d ago
TRVI
Trevi Therapeutics Targets IPF Chronic Cough With New Phase 3 Trial
PremiumCompany Announcements
Trevi Therapeutics Targets IPF Chronic Cough With New Phase 3 Trial
26d ago
TRVI
Trevi Therapeutics Shareholders Approve Stock and Governance Changes
PremiumCompany AnnouncementsTrevi Therapeutics Shareholders Approve Stock and Governance Changes
2M ago
8K
TRVI
Trevi Therapeutics price target raised to $30 from $18 at Stifel
Premium
The Fly
Trevi Therapeutics price target raised to $30 from $18 at Stifel
3M ago
TRVI
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
Premium
The Fly
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
3M ago
TRVI
Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
PremiumThe Fly
Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
3M ago
TRVI
Trevi Therapeutics Charts Cash-Rich Path Through Key Trials
PremiumCompany Announcements
Trevi Therapeutics Charts Cash-Rich Path Through Key Trials
3M ago
TRVI
Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
PremiumRatings
Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
3M ago
TRVI
Unusually active option classes on open April 17th
PremiumThe Fly
Unusually active option classes on open April 17th
4M ago
UBS
UMC
Trevi Therapeutics Prices Public Offering to Fund Haduvio
PremiumCompany AnnouncementsTrevi Therapeutics Prices Public Offering to Fund Haduvio
4M ago
8K
TRVI
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
Premium
The Fly
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
4M ago
TRVI
Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board
Premium
The Fly
Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board
4M ago
AA
CNS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >